This is a tech company if you look at where they are investing and read about the ClearAg patents and competitive advantages. To get someone with high level expertise and experience should be well received by investors. It's been 7 months. I hope they are zeroing in.
I've reviewed the last few conference call transcripts since Michleson came on board and can't find anything about 19 contracts. When were these contracts mentioned?
After becoming CEO he said there was a strong foundation on which to turn the company around and he spelled out the strategy quite specifically. Only in the last call did CC did he really sound very well pleased that the turnaround is taking place.
The financials are real garbage right now but we have a new CEO, divestitures, cost cutting, new products getting a big response and a new sales VP who used to be Sales VP at a company with 10 times the Cap of RMGN.
I think the stock presents a buy. I agree with Roth Capital. buy now. Sell later for a profit because it is a turnaround. IMO.
Craig-Hallum Capital Group LLC
Ordinary research won't uncover stocks with extraordinary potential.
The Alpha-Select List
Alpha Select Conference
Deep Research. Tough Criteria. Enormous Potential. Discovering hidden investment opportunities that have enormous potential. That’s what our research team strives to identify with the Craig-Hallum Alpha Select List. The list is an actively researched and managed collection of under-followed, micro-cap companies we believe have the potential for significant growth. To make the list, each stock must meet some tough criteria: above average growth prospects, attractive business models, unappreciated value and strong management teams just for starters. Many of these micro-cap companies are discovered while our analysts are diligently researching within their sectors of expertise. Sometimes they uncover hidden opportunities that defy traditional sector description. Because few analysts focus on these unconventional sector businesses, the potential for maximum investment returns is truly extraordinary.
©2015 Craig-Hallum Capital Group LLC. All Rights Reserved. Member FINRA and SIPC.
Interesting theory. Chartwatcher must be getting everyone to buy. Including insiders.
Here's another theory. There is a pipeline of deals mentioned in last CC. Recently there are more buyers of the stock than sellers based on that pipeline, the book value being $1.72 and the increasing margins and revs. recently reported.
Mitek knows by now what works in the market place since they have a few products out there. ID checker has been around for over ten years. Maybe the capture tech that Mitek adds and the channel partners in the USA make for the synergies.
It could be way bigger than MD and unlike checks- no end in sight. I hope they can ramp things up pretty fast with some announcements.
But right now I'll rate the way MITK is trading today in an up market. Yesterday I rated it B. Today it's D plus. It needs to get over the $3.40 mark. So right now it's a little lackluster and nothing to get excited about over the short term.
Looking good! Moving out of a nice base. I'm hoping for a good presentation coming up and really upbeat CC. A new CEO would be killer good.
I just saw a video today where one third of all small caps have no earnings. DYSL, I would call a nano cap. The earnings could rise by a tiny dollar amount and the PE would be improved exponentially.
What's more important are the improving top line, with new contracts and the leveling off of the Contract business- which I assume is lower margined anyway.
The overall metrics are improving even with the $25M drag per Q from Xcede.
So the MAYO is involved in Xcede and you have the patent and the refining of the properties patch. I'd think a poor PE ratio won't matter much if you are short and they announce private equity deal. Seems crazy to be short but there are shares short.
I'm curious as to your take on the Xcede patch and I went so far as to read some of your other posts- you seem to possibly have some medical training.
If they can get funding for this and some medically oriented investors take an equity position, the stock could skyrocket because it would be perceived as a validation of the product, which is targeting a big market.
I'm hoping for an explosion. I think a lot of us are!!!
Looking pretty good in a bad market.
I said I'd add if insiders buy, so I did again- - even if it may be getting toppy.
Last market sell-off we had I rated MITK a C+, based on how it held up- but today, so far it's a B.
Needs to break close over $3.40 and refuse to go lower in order to turn more bullish. Earnings have been good. Nice growth, last 5 Q's. Back off the non recurring expense and it's turning quite profitable.
Mobile Photo Pay was not a complete dud but the most recent attempt at getting a better suite of products involved buying an existing, growing business with a track record to judge it's products by.
If it works, look out.
Recent article about online identity verification:
Black is beautiful. EBITDA must be fixed. New CEO makes a lot of progress but we need more for a turnaround.
Adjusted EBITDA from continuing operations in the second quarter of 2015 was negative $2.4 million compared to a negative $1.6 million in the first quarter of 2015. The sequential decline in adjusted EBITDA resulted largely from an increase in operating expenses during the quarter. The increase in operating expenses resulted from an increase in professional fees such as legal, audit, tax and shareholder-related expenses related to a number of complex nonrecurring transactions taking place in the quarter such as the divestiture of the Airline Media Network business and the conversion of our convertible preferred stock into common shares.
I just want to mention biotech AXGN did perform well from where I had it at $2.50. It's my 2nd biggest micro cap after ARIS, then ITI, followed closely by DYSL. They had some good top line last Q but what sent it to over $5 was the equity funding that also brought some super expertise to their BOD.
So this makes me think DYSL, with it's miniscule float may go crazy to the upside if they too can get some funding and bring some validation to the strategy to take it through to FDA.
If you like low priced turnaround plays, read last transcript of RMGN- it sounds ripe to me and I took a tiny position.
In the last CC they downplayed the near term opportunities for connected vehicle revenues but this is a nice chunk to add to the top line growth. Margins continue to grow. Top line continues to grow. Ag products seem to be ready for a slow but steady, high margin ramp. Insider buying. Connected vehicles are a tailwind. Any more contracts like this and we could see a lot more legs to this breakout.
Nice news. From last CC:
Edward M. Woo - Ascendiant Capital
Yeah, thank you for as well as congratulations on a very great quarter. I did have a question, you mentioned about some of the movements you are doing in international. Should we expect more news over the next year on your focus and expansion in that area and do you see opportunities not just in Europe but also in Asia or emerging markets?
Roy W. Olivier - President and CEO
That’s a great question. I mean we do continue to see -- we do expect to continue to see some improved new bookings performance and ultimately revenue from our European operation. That said every year as we prioritize where we are investing for growth in the future we typically are investing in projects that will drive growth in the domestic market and we don’t make a tremendous amount of investments in Europe. So I don’t expect Europe to suddenly start to double or triple in size but I do expect continued stronger new bookings and ultimately stronger revenue.